Analysts Set Expectations for Zoetis' Q1 Earnings (NYSE:ZTS)

Zoetis Inc. (NYSE:ZTS - Free Report) - Zacks Research decreased their Q1 2025 earnings per share (EPS) estimates for shares of Zoetis in a report released on Thursday, March 6th. Zacks Research analyst E. Bagri now anticipates that the company will post earnings of $1.39 per share for the quarter, down from their prior forecast of $1.45. The consensus estimate for Zoetis' current full-year earnings is $6.07 per share. Zacks Research also issued estimates for Zoetis' Q2 2025 earnings at $1.60 EPS, Q3 2025 earnings at $1.62 EPS, Q4 2025 earnings at $1.46 EPS, FY2025 earnings at $6.07 EPS, Q1 2026 earnings at $1.54 EPS, Q2 2026 earnings at $1.66 EPS, Q3 2026 earnings at $1.69 EPS and FY2027 earnings at $6.97 EPS.

Zoetis (NYSE:ZTS - Get Free Report) last issued its earnings results on Thursday, February 13th. The company reported $1.40 earnings per share for the quarter, beating analysts' consensus estimates of $1.37 by $0.03. The business had revenue of $2.32 billion during the quarter, compared to analyst estimates of $2.30 billion. Zoetis had a return on equity of 53.82% and a net margin of 26.86%.

ZTS has been the subject of a number of other reports. Barclays lifted their target price on Zoetis from $242.00 to $244.00 and gave the company an "overweight" rating in a research report on Friday, February 14th. Piper Sandler boosted their price target on Zoetis from $200.00 to $205.00 and gave the stock an "overweight" rating in a research report on Thursday, February 27th. Stifel Nicolaus reduced their price target on Zoetis from $210.00 to $180.00 and set a "buy" rating for the company in a research report on Tuesday, January 7th. Morgan Stanley reduced their price target on Zoetis from $243.00 to $238.00 and set an "overweight" rating for the company in a research report on Friday, February 14th. Finally, Leerink Partnrs raised Zoetis to a "strong-buy" rating in a research report on Monday, December 2nd. One analyst has rated the stock with a hold rating, ten have issued a buy rating and two have given a strong buy rating to the stock. Based on data from MarketBeat, the company has a consensus rating of "Buy" and a consensus price target of $215.90.

Remove Ads

Zoetis Stock Up 1.8 %

NYSE ZTS traded up $3.09 on Friday, reaching $170.34. 3,296,788 shares of the stock traded hands, compared to its average volume of 3,274,650. The company has a debt-to-equity ratio of 1.09, a quick ratio of 1.08 and a current ratio of 1.75. The company has a fifty day moving average price of $166.72 and a 200-day moving average price of $176.78. The company has a market cap of $76.28 billion, a price-to-earnings ratio of 31.14, a PEG ratio of 2.78 and a beta of 0.94. Zoetis has a 12 month low of $144.80 and a 12 month high of $200.33.

Institutional Trading of Zoetis

A number of hedge funds have recently modified their holdings of the stock. Menard Financial Group LLC boosted its stake in shares of Zoetis by 11.4% in the fourth quarter. Menard Financial Group LLC now owns 1,957 shares of the company's stock worth $319,000 after buying an additional 201 shares during the last quarter. Universal Beteiligungs und Servicegesellschaft mbH acquired a new position in Zoetis in the 4th quarter worth about $87,984,000. Azzad Asset Management Inc. ADV raised its holdings in Zoetis by 1.7% in the 4th quarter. Azzad Asset Management Inc. ADV now owns 11,741 shares of the company's stock worth $1,913,000 after purchasing an additional 196 shares during the period. Capital A Wealth Management LLC acquired a new position in Zoetis in the 4th quarter worth about $259,000. Finally, Cypress Asset Management Inc. TX acquired a new position in Zoetis in the 4th quarter worth about $4,593,000. Hedge funds and other institutional investors own 92.80% of the company's stock.

Insider Transactions at Zoetis

In other news, EVP Roxanne Lagano sold 326 shares of the company's stock in a transaction dated Tuesday, February 11th. The stock was sold at an average price of $171.18, for a total value of $55,804.68. Following the sale, the executive vice president now owns 16,107 shares in the company, valued at $2,757,196.26. This represents a 1.98 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Company insiders own 0.16% of the company's stock.

Zoetis Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Tuesday, June 3rd. Shareholders of record on Monday, April 21st will be paid a dividend of $0.50 per share. The ex-dividend date of this dividend is Monday, April 21st. This represents a $2.00 annualized dividend and a yield of 1.17%. Zoetis's payout ratio is presently 36.56%.

Zoetis Company Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.